Mammary Cell News

Mammary Cell News is an online resource covering the latest research into breast cancer and mammary cells.

SURGE Therapeutics Completes Phase I Dosing of First-in-Category Intraoperative Immunotherapy and Prepares for Registrational Trial

February 18, 2026

[SURGE Therapeutics (Business Wire, Inc.)] SURGE Therapeutics announced the final patient has been dosed in its Phase I clinical trial of SRG-514, an investigational therapy for breast cancer patients undergoing surgery.

PKC-Eta Promotes Breast Cancer Metastasis by Regulating the Hippo-YAP Signaling Pathway

February 18, 2026

[Signal Transduction and Targeted Therapy] Using genetic ablation studies, investigators showed that Protein kinase C-eta (PKCη)- promotes metastasis by enhancing epithelial‒mesenchymal transition and stemness. Notably, compared with those in PKCη-intact tumors, orthotopic xenografts of PKCη-knockout cells in NSG mice resulted in reduced tumor growth and metastasis.

Induction of Senescence during Postpartum Mammary Gland Involution Supports Tissue Remodeling and Promotes Postpartum Tumorigenesis

February 18, 2026

[Nature Aging] Researchers showed that during mammary gland involution in mice, a p16^Ink4a-dependent senescence response is induced in alveolar luminal cells. Eliminating senescent cells disrupts tissue remodeling and delays involution, demonstrating their physiological importance.

KDM5B Cooperates with CRL4B Complex to Promote the Tumorigenesis of ER+ Breast Cancer via Regulating Cholesterol Metabolism

February 18, 2026

[Cell Death & Disease] Scientists investigated the functional interplay between lysine demethylase 5B (KDM5B) and the Cullin-RING ligase 4B (CRL4B) complex in modulating cholesterol metabolism to promote estrogen receptor-positive (ER+) breast cancer progression.

KDM6A Alternative Splicing Induced by 25(OH)D Inhibits Breast Cancer Cell Stemness through Repressing TRAP1 Transcription

February 18, 2026

[Oncogene] Investigators revealed that 25-Hydroxyvitamin D (25(OH)D) exerts antitumor effects by promoting exon 13 skipping of KDM6A, which suppresses the proliferation and stemness of breast cancer cells and lacks H3K27 demethylase activity.

Estrogen Receptor β Target Gene Expression Reveals Novel Repressive Functions in Aggressive Breast Cancer

February 18, 2026

[NPJ Breast Cancer] By cross-examining responsive mRNAs and miRNAs against chromatin binding sites in inflammatory breast cancer cells with agonist-activated transfected and endogenous estrogen receptor β, researchers identified key regulatory binding motifs, direct targets, and associated biological functions.

Structural Determinants of Glycosaminoglycan Oligosaccharides As LL-37 Inhibitors in Breast Cancer

February 18, 2026

[Glycobiology] Scientists investigated the ability of structurally distinct glycosaminoglycan oligosaccharides to inhibit LL-37-mediated responses in MDA-MB-231 breast cancer cells.

LBPs NPs Suppress Breast Cancer Progression by Inhibiting YAP1 Expression to Induce Ferroptosis and Alter Energy Metabolism

February 18, 2026

[Scientific Reports] Researchers investigated the antitumor properties of Lycium barbarum polysaccharides (LBPs) and develops LBPs-loaded poly(lactic-co-glycolic acid) nanoparticles (LBPs NPs), further exploring the mechanisms of free LBPs and LBPs NPs in normal and malignant breast cells.

Transforming Growth Factor-β and Integrins: Key Players in EMT and Breast Cancer Progression

February 18, 2026

[Cancer Cell International] The authors examine how integrins, especially αvβ3, αvβ6, and β1, serve as critical modulators of transforming growth factor-β signaling and play a key role in epithelial-to-mesenchymal transition (EMT), immune evasion, angiogenesis, and extracellular matrix remodeling.

Extracellular Matrix Mediates Circulating Tumor Cell Clustering in Triple-Negative Breast Cancer Metastasis

February 12, 2026

[Nature Communications] Researchers showed that the ECM component hyaluronan mediates adherens junction-independent circulating tumor cell clustering in triple-negative breast cancers.

Aminex Therapeutics Announces Multiple Sites Activated for Phase Ib/II Clinical Trial of Novel Investigational Cancer Treatment AMXT 1501 and DFMO in Patients with Solid...

February 5, 2026

[Aminex Therapeutics, Inc.] Aminex Therapeutics, Inc. announced the initiation of & first patient treated in a Phase 1b/2 clinical trial of AMXT 1501 in combination with difluoromethylornithine (DFMO) in patients with breast cancer or metastatic melanoma.

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase Ib Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

February 5, 2026

[Kazia Therapeutics Limited] Kazia Therapeutics provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage, Stage IV, metastatic TNBC.

For over a decade, Mammary Cell News has been keeping the global scientific and medical communities informed about the latest research, reviews, and news in the field of mammary tissues. Our editors gather publications on the topic of mammary cell differentiation and characterization, as well as the progression and treatment of breast cancer. We also keep scientists up-to-date on the latest policy changes, job postings, and events.